drugset
drugset / Trial / NCT05986877

A Study of STSA-1201 in Healthy Subjects

NCT05986877 ↗

Phase 1 Completed 44 enrolled Staidson (Beijing) Biopharmaceuticals Co., Ltd
RandomizedSequentialQuadruple-blindTreatment

Summary

This study is a Phase Ia, randomized, double-blind, placebo-controlled, single dose, dose escalation safety, tolerability, and pharmacokinetic study of STSA-1201 injection in healthy subjects. A total of 44 healthy subjects were enrolled in four dosage groups.

Timeline

Start
2023-08-04
Primary completion
2024-03-14
Completion
2024-03-14

Drugs

EvaluationDrugModalityDoseRoute
Subject STSA-1201 Unknown — Subcutaneous

Indications

No indication recorded.